VRS now offers validated antiviral and neutralisation assay services for Human Metapneumovirus (hMPV).

hMPV is a leading cause of acute respiratory tract infections worldwide, particularly in young children, the elderly, and immunocompromised individuals. Despite its significant clinical burden, there are currently no approved vaccines or specific antiviral treatments.

With growing interest in respiratory virus countermeasures, hMPV has become a key focus for antiviral research and vaccine development programmes.

Our assays are designed to deliver reliable, reproducible data, allowing teams to bypass lengthy assay development and move directly into compound screening and lead optimisation.

Contact us to learn more about our hMPV assay capabilities and how we can support and accelerate your antiviral development pipeline.